Evaluation of efficacy of combined topical Bimatoprost and Fractionated carbon dioxide laser versus Bimatoprost alone in treatment of alopecia areata
Phase 2
Recruiting
- Conditions
- Alopecia areata.Alopecia areata
- Registration Number
- IRCT20210715051895N1
- Lead Sponsor
- Kerman University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Alopecia areata patients who have two similar alopecia patches on the scalp
Exclusion Criteria
pregnancy
lactation
history of allergy to prostaglandin analouge
Taking medication or treatment for the past three months that affects the hair cycle
Uncontrolled systemic disease
Non-patchy alopecia areata and involving area other than the scalp
photosensivity
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Alopecia patch area. Timepoint: at base line ,4,8,12,24 weeks later. Method of measurement: Measurement of hair regrowth rate by physical examination based on Salt score scale.;Patient satisfaction. Timepoint: 4,8,12,24 weeks later. Method of measurement: By 7point global-assessment patient satisfaction questionnaire.
- Secondary Outcome Measures
Name Time Method Erythema. Timepoint: 4,8,12 Weeks from the beginning of treatment. Method of measurement: By clinical examination and classification of severity of complications into mild, moderate and severe.;Scaling. Timepoint: 4,8,12 Weeks from the beginning of treatment. Method of measurement: By clinical examination and classification of severity of complications into mild, moderate and severe.;Skin dryness. Timepoint: 4,8,12 Weeks from the beginning of treatment. Method of measurement: By clinical examination and classification of severity of complications into mild, moderate and severe.;Pruritis. Timepoint: 4,8,12 Weeks from the beginning of treatment. Method of measurement: By clinical examination and classification of severity of complications into mild, moderate and severe.